Summary

The global Inactivated Veterinary Vaccines market is projected to grow from US$ 4137 million in 2025 to US$ 6352 million by 2032, at a CAGR of 6.4% (2026-2032), driven by critical product segments and diverse end‑use applications.
Inactivated Veterinary Vaccines are biological preparations designed to induce protective immune responses in animals using pathogenic microorganisms or their antigenic components that have been rendered noninfectious through validated physical or chemical inactivation processes. These vaccines retain antigenic structures capable of stimulating immune recognition while preventing the replication of the original pathogens. Manufacturing generally involves pathogen cultivation, antigen harvesting, controlled inactivation, purification, formulation, and quality testing. Inactivation methods may involve formaldehyde, beta-propiolactone, or other validated agents, depending on the pathogen and production process. Adjuvants are frequently incorporated to enhance immune responses, particularly when sustained antibody production is required. Inactivated veterinary vaccines are administered through appropriate vaccination schedules to prevent infectious diseases, reduce clinical severity, and support animal health management. Their commercial and clinical performance depends on antigen integrity, immunogenicity, safety, formulation stability, and consistency between production batches.
Key Findings
Inactivated Veterinary Vaccines represent an established category of preventive veterinary biological products for livestock, poultry, companion animals, and aquaculture
The Inactivated Veterinary Vaccines market encompasses viral, bacterial, and mixed-pathogen formulations with distinct manufacturing and immunological requirements
Inactivated Veterinary Vaccines for poultry and swine farming are important components of commercial livestock disease prevention programs
Oil-adjuvanted Inactivated Veterinary Vaccines are widely used in selected livestock and poultry immunization programs
The Inactivated Veterinary Vaccines competitive landscape includes multinational animal health companies and specialized veterinary vaccine manufacturers
Market Trends
The Inactivated Veterinary Vaccines industry is undergoing a gradual transition from conventional pathogen inactivation toward more precisely controlled antigen production, optimized adjuvant formulations, and integrated disease prevention solutions. Improvements in cell culture systems, antigen purification, inactivation validation, and formulation technologies are supporting greater manufacturing consistency and more predictable immunogenicity. In commercial livestock production, vaccine development increasingly emphasizes compatibility with intensive farming systems, practical vaccination schedules, and protection against locally circulating pathogen variants. Multivalent and combination formulations are receiving attention because they can simplify vaccination management where several diseases must be controlled simultaneously. Meanwhile, the growing importance of animal welfare, antimicrobial stewardship, and preventive veterinary medicine is encouraging vaccine manufacturers to strengthen product differentiation through safety, duration of immunity, antigenic relevance, and field performance. Digital livestock health monitoring and improved veterinary diagnostic capabilities are also facilitating more targeted immunization strategies, linking vaccine selection more closely with epidemiological surveillance and herd-level disease management.
Market Dynamics
Drivers
The principal demand drivers for Inactivated Veterinary Vaccines include the continuing economic impact of infectious animal diseases, increasing requirements for biosecurity in commercial farming, and the need to maintain predictable production performance in livestock and poultry operations. Disease outbreaks can cause mortality, reduced productivity, movement restrictions, and substantial disruption to animal product supply chains, making preventive vaccination an important component of risk management. In addition, veterinary authorities and livestock producers increasingly emphasize coordinated disease prevention, surveillance, and vaccination programs. Demand is also supported by expanding veterinary services, greater attention to companion animal preventive care, and improvements in disease monitoring across emerging livestock production regions.
Restraints
The Inactivated Veterinary Vaccines market faces limitations associated with production costs, antigen manufacturing complexity, vaccination logistics, and differences in immune responses across animal species and pathogens. Many inactivated formulations require adjuvants or repeated administration to achieve the desired level and duration of protection, increasing the operational burden on livestock producers. Manufacturing requires validated inactivation procedures, strict biological safety controls, and comprehensive batch-release testing, which contribute to capital requirements and production expenses. Cold-chain distribution, veterinary administration capacity, and vaccination compliance may also constrain adoption in geographically dispersed farming systems. Furthermore, vaccine performance can be affected by antigenic variation, maternal antibodies, and differences between laboratory efficacy and field conditions.
Opportunities
Commercial opportunities are emerging in improved multivalent formulations, pathogen-specific vaccine development, advanced adjuvant systems, and regional manufacturing capacity expansion. In poultry and swine production, manufacturers can create additional value by developing formulations compatible with established vaccination schedules and the disease profiles of different farming systems. In companion animal healthcare, broader access to preventive veterinary services creates opportunities for established inactivated vaccine products and appropriately differentiated formulations. Aquaculture represents another development area where disease-specific vaccines, suitable delivery methods, and improved manufacturing economics may support wider commercial adoption. Localized production, stronger veterinary distribution networks, and collaboration with animal health authorities can further improve market access, particularly in regions seeking greater security of veterinary biological product supply.
Challenges
Long-term challenges in the Inactivated Veterinary Vaccines industry include pathogen evolution, regulatory complexity, biological manufacturing consistency, and the commercial uncertainty associated with emerging animal diseases. Changes in circulating strains may reduce the relevance of existing vaccine antigens and require additional development, testing, or regulatory approval. Manufacturers must also demonstrate consistent antigen potency, complete inactivation, acceptable safety, and appropriate efficacy under applicable regulatory requirements. Competition from live attenuated, recombinant, vector-based, and other vaccine technologies creates pressure to improve protection and operational convenience. In price-sensitive livestock markets, suppliers must balance manufacturing quality and immunological performance against customers' willingness to pay, while maintaining reliable supply during periods of heightened disease prevention demand.
Industry Chain Analysis
The Inactivated Veterinary Vaccines industry chain consists of upstream biological materials and manufacturing inputs, midstream vaccine development and production, and downstream veterinary distribution and animal immunization services. Upstream activities involve pathogen strains or antigen sources, cell culture media, embryonated eggs where applicable, bioreactor equipment, inactivation agents, adjuvants, stabilizers, packaging materials, and quality control reagents. The reliability of these inputs directly affects antigen yield, product consistency, and manufacturing costs. Midstream production typically includes antigen cultivation, harvesting, inactivation, purification, formulation, aseptic filling, and batch-release testing. The most technically sensitive stages involve maintaining antigenic integrity while ensuring complete inactivation and consistent potency. Manufacturers with established biological production platforms, validated quality systems, and regulatory expertise are generally better positioned to manage process variability and scale manufacturing.
Downstream participants include veterinary distributors, animal health service providers, livestock integrators, commercial farms, veterinary clinics, and aquaculture operators. Product value is created not only through vaccine manufacturing but also through disease-specific formulation, regulatory registration, cold-chain management, veterinary technical support, and reliable product availability. The cost structure is influenced by antigen production efficiency, adjuvant and formulation requirements, quality assurance, production scale, and distribution conditions. Companies capable of combining consistent manufacturing quality with practical vaccination solutions can strengthen customer relationships and improve their position in recurring animal disease prevention programs.
Segment Insights
The Inactivated Veterinary Vaccines market can be divided into inactivated viral vaccines, inactivated bacterial vaccines, and mixed-pathogen inactivated vaccines based on pathogen composition. Inactivated viral vaccines are an important product category in poultry, livestock, and companion animal healthcare, with applications involving diseases such as avian influenza, Newcastle disease, rabies, and selected livestock viral infections, subject to local registration and vaccination policies. Their competitive performance depends on antigenic matching, immunogenicity, safety, and production consistency. Inactivated bacterial vaccines, including bacterin-based products, address bacterial disease prevention requirements in livestock and other animals. These formulations may require careful antigen selection and adjuvant optimization to achieve appropriate protection. Mixed-pathogen formulations combine antigens targeting different infectious agents, creating value where coordinated prevention of multiple diseases is operationally advantageous.
Downstream Market Opportunities
Poultry farming and swine production are important commercial applications for Inactivated Veterinary Vaccines because infectious disease prevention is closely linked to flock and herd productivity, mortality control, and production continuity. In poultry farming, inactivated vaccines are used in selected vaccination programs targeting diseases such as Newcastle disease and avian influenza, depending on regional epidemiology and regulatory requirements. Commercial customers include integrated poultry producers, breeding companies, and veterinary service organizations. Procurement decisions emphasize protective efficacy, antigenic relevance, vaccine safety, batch consistency, administration efficiency, and total vaccination cost. In swine production, inactivated vaccines are used against selected viral and bacterial pathogens as part of coordinated herd health programs. Large producers typically evaluate vaccines according to disease control performance, compatibility with herd vaccination schedules, and the economic consequences of infection.
Cattle, companion animal healthcare, and aquaculture offer additional differentiated opportunities. In cattle production, inactivated vaccines are applied in disease prevention programs where herd-level protection, reproductive performance, and farm biosecurity are important. Companion animal applications include established preventive vaccination programs, particularly rabies vaccination, with demand supported by veterinary clinic services and routine preventive care. Aquaculture vaccination is more dependent on species, pathogen characteristics, administration methods, and production economics, creating opportunities for disease-specific formulations and improved delivery solutions. Across these downstream markets, manufacturers can expand commercial participation through targeted product registration, veterinary technical support, localized antigen selection, improved formulation stability, and partnerships with major animal production customers. The strongest opportunities are associated with demonstrable disease control benefits and practical improvements in vaccination management rather than product differentiation based solely on formulation complexity.
Regional Insights
North America and Europe represent established markets for Inactivated Veterinary Vaccines, supported by developed veterinary healthcare infrastructure, commercial livestock production, regulatory oversight, and established animal disease prevention practices. The United States has an extensive animal health industry serving cattle, swine, poultry, and companion animals, while European markets place considerable emphasis on animal welfare, disease surveillance, veterinary product quality, and coordinated livestock health management. Product adoption differs by country because vaccination policies, disease prevalence, farming structures, and regulatory authorization requirements are not uniform. In these mature markets, commercial competition increasingly depends on product reliability, differentiated protection, veterinary relationships, and the ability to support integrated animal health programs.
Asia-Pacific is an important production and demand region, particularly because of its substantial poultry, swine, and aquaculture industries. China and other major Asian livestock-producing countries generate demand for veterinary vaccines adapted to local pathogen circulation and intensive farming conditions. Regional opportunities include domestic manufacturing development, improvement of biological production technologies, broader veterinary service coverage, and more systematic disease prevention programs. Latin America represents another significant livestock-oriented market, with vaccination requirements linked to cattle production, poultry farming, and export-related animal health management. In the Middle East and Africa, market development is influenced by livestock disease control priorities, veterinary infrastructure, government vaccination initiatives, and distribution capabilities. Regional growth potential therefore depends on the interaction between animal population structure, disease epidemiology, purchasing capacity, and veterinary healthcare accessibility.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Inactivated Veterinary Vaccines market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck
Zoetis
Boehringer Ingelheim
Ceva
CAHIC
HVRI
Ringpu Biology
Yebio
DHN
WINSUN
Elanco
Virbac
Jinyu Bio-Technology
ChengDu Tecbond
CAVAC
Kyoto Biken Laboratories
FATRO
Vaksindo
Bio-Labs
Avimex Animal Health
MEVAC
Biovac
Atafen
Dyntec
RVSRI
Medion
Segment by Type
Inactivated Viral Vaccines
Inactivated Bacterial Vaccines
Other
Segment by Adjuvanted
Oil-Adjuvanted Inactivated Vaccines
Aluminum-Adjuvanted Inactivated Vaccines
Other
Segment by Vaccine Combination
Monovalent Vaccines
Multivalent Vaccines
Combination Vaccines
Segment by Application
Farm Animal
Companion Animal
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Inactivated Veterinary Vaccines study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Inactivated Veterinary Vaccines: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Inactivated Veterinary Vaccines Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Inactivated Viral Vaccines
1.2.3 Inactivated Bacterial Vaccines
1.2.4 Other
1.3 Market Segmentation by Adjuvanted
1.3.1 Global Inactivated Veterinary Vaccines Market Size by Adjuvanted, 2021 vs 2025 vs 2032
1.3.2 Oil-Adjuvanted Inactivated Vaccines
1.3.3 Aluminum-Adjuvanted Inactivated Vaccines
1.3.4 Other
1.4 Market Segmentation by Vaccine Combination
1.4.1 Global Inactivated Veterinary Vaccines Market Size by Vaccine Combination, 2021 vs 2025 vs 2032
1.4.2 Monovalent Vaccines
1.4.3 Multivalent Vaccines
1.4.4 Combination Vaccines
1.5 Market Segmentation by Application
1.5.1 Global Inactivated Veterinary Vaccines Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Farm Animal
1.5.3 Companion Animal
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Inactivated Veterinary Vaccines Revenue Estimates and Forecasts (2021-2032)
2.2 Global Inactivated Veterinary Vaccines Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Inactivated Veterinary Vaccines Sales Estimates and Forecasts (2021-2032)
2.4 Global Inactivated Veterinary Vaccines Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Inactivated Veterinary Vaccines Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Inactivated Veterinary Vaccines Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Inactivated Viral Vaccines: Market Share by Key Manufacturers
3.5.2 Inactivated Bacterial Vaccines: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Inactivated Veterinary Vaccines Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Inactivated Veterinary Vaccines Sales Performance by Type
4.1.1 Global Inactivated Veterinary Vaccines Sales Volume by Type (2021-2032)
4.1.2 Global Inactivated Veterinary Vaccines Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Inactivated Veterinary Vaccines Sales Performance by Adjuvanted
4.2.1 Global Inactivated Veterinary Vaccines Sales Volume by Adjuvanted (2021-2032)
4.2.2 Global Inactivated Veterinary Vaccines Revenue by Adjuvanted (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Adjuvanted (2021-2032)
4.3 Global Inactivated Veterinary Vaccines Sales Performance by Vaccine Combination
4.3.1 Global Inactivated Veterinary Vaccines Sales Volume by Vaccine Combination (2021-2032)
4.3.2 Global Inactivated Veterinary Vaccines Revenue by Vaccine Combination (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Vaccine Combination (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Inactivated Veterinary Vaccines Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Inactivated Veterinary Vaccines Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Inactivated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Inactivated Veterinary Vaccines Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Inactivated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Inactivated Veterinary Vaccines Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Inactivated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Inactivated Veterinary Vaccines Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Inactivated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Inactivated Veterinary Vaccines Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Inactivated Veterinary Vaccines Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Inactivated Veterinary Vaccines Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Merck
11.1.1 Merck Corporation Information
11.1.2 Merck Business Overview
11.1.3 Merck Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.1.4 Merck Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Merck Inactivated Veterinary Vaccines Sales by Product in 2025
11.1.6 Merck Inactivated Veterinary Vaccines Sales by Application in 2025
11.1.7 Merck Inactivated Veterinary Vaccines Sales by Geographic Area in 2025
11.1.8 Merck Inactivated Veterinary Vaccines SWOT Analysis
11.1.9 Merck Recent Developments
11.2 Zoetis
11.2.1 Zoetis Corporation Information
11.2.2 Zoetis Business Overview
11.2.3 Zoetis Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.2.4 Zoetis Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Zoetis Inactivated Veterinary Vaccines Sales by Product in 2025
11.2.6 Zoetis Inactivated Veterinary Vaccines Sales by Application in 2025
11.2.7 Zoetis Inactivated Veterinary Vaccines Sales by Geographic Area in 2025
11.2.8 Zoetis Inactivated Veterinary Vaccines SWOT Analysis
11.2.9 Zoetis Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Corporation Information
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.3.4 Boehringer Ingelheim Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Boehringer Ingelheim Inactivated Veterinary Vaccines Sales by Product in 2025
11.3.6 Boehringer Ingelheim Inactivated Veterinary Vaccines Sales by Application in 2025
11.3.7 Boehringer Ingelheim Inactivated Veterinary Vaccines Sales by Geographic Area in 2025
11.3.8 Boehringer Ingelheim Inactivated Veterinary Vaccines SWOT Analysis
11.3.9 Boehringer Ingelheim Recent Developments
11.4 Ceva
11.4.1 Ceva Corporation Information
11.4.2 Ceva Business Overview
11.4.3 Ceva Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.4.4 Ceva Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Ceva Inactivated Veterinary Vaccines Sales by Product in 2025
11.4.6 Ceva Inactivated Veterinary Vaccines Sales by Application in 2025
11.4.7 Ceva Inactivated Veterinary Vaccines Sales by Geographic Area in 2025
11.4.8 Ceva Inactivated Veterinary Vaccines SWOT Analysis
11.4.9 Ceva Recent Developments
11.5 CAHIC
11.5.1 CAHIC Corporation Information
11.5.2 CAHIC Business Overview
11.5.3 CAHIC Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.5.4 CAHIC Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 CAHIC Inactivated Veterinary Vaccines Sales by Product in 2025
11.5.6 CAHIC Inactivated Veterinary Vaccines Sales by Application in 2025
11.5.7 CAHIC Inactivated Veterinary Vaccines Sales by Geographic Area in 2025
11.5.8 CAHIC Inactivated Veterinary Vaccines SWOT Analysis
11.5.9 CAHIC Recent Developments
11.6 HVRI
11.6.1 HVRI Corporation Information
11.6.2 HVRI Business Overview
11.6.3 HVRI Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.6.4 HVRI Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 HVRI Recent Developments
11.7 Ringpu Biology
11.7.1 Ringpu Biology Corporation Information
11.7.2 Ringpu Biology Business Overview
11.7.3 Ringpu Biology Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.7.4 Ringpu Biology Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Ringpu Biology Recent Developments
11.8 Yebio
11.8.1 Yebio Corporation Information
11.8.2 Yebio Business Overview
11.8.3 Yebio Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.8.4 Yebio Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Yebio Recent Developments
11.9 DHN
11.9.1 DHN Corporation Information
11.9.2 DHN Business Overview
11.9.3 DHN Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.9.4 DHN Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 DHN Recent Developments
11.10 WINSUN
11.10.1 WINSUN Corporation Information
11.10.2 WINSUN Business Overview
11.10.3 WINSUN Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.10.4 WINSUN Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 WINSUN Recent Developments
11.11 Elanco
11.11.1 Elanco Corporation Information
11.11.2 Elanco Business Overview
11.11.3 Elanco Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.11.4 Elanco Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Elanco Recent Developments
11.12 Virbac
11.12.1 Virbac Corporation Information
11.12.2 Virbac Business Overview
11.12.3 Virbac Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.12.4 Virbac Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Virbac Recent Developments
11.13 Jinyu Bio-Technology
11.13.1 Jinyu Bio-Technology Corporation Information
11.13.2 Jinyu Bio-Technology Business Overview
11.13.3 Jinyu Bio-Technology Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.13.4 Jinyu Bio-Technology Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Jinyu Bio-Technology Recent Developments
11.14 ChengDu Tecbond
11.14.1 ChengDu Tecbond Corporation Information
11.14.2 ChengDu Tecbond Business Overview
11.14.3 ChengDu Tecbond Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.14.4 ChengDu Tecbond Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 ChengDu Tecbond Recent Developments
11.15 CAVAC
11.15.1 CAVAC Corporation Information
11.15.2 CAVAC Business Overview
11.15.3 CAVAC Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.15.4 CAVAC Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 CAVAC Recent Developments
11.16 Kyoto Biken Laboratories
11.16.1 Kyoto Biken Laboratories Corporation Information
11.16.2 Kyoto Biken Laboratories Business Overview
11.16.3 Kyoto Biken Laboratories Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.16.4 Kyoto Biken Laboratories Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Kyoto Biken Laboratories Recent Developments
11.17 FATRO
11.17.1 FATRO Corporation Information
11.17.2 FATRO Business Overview
11.17.3 FATRO Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.17.4 FATRO Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 FATRO Recent Developments
11.18 Vaksindo
11.18.1 Vaksindo Corporation Information
11.18.2 Vaksindo Business Overview
11.18.3 Vaksindo Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.18.4 Vaksindo Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Vaksindo Recent Developments
11.19 Bio-Labs
11.19.1 Bio-Labs Corporation Information
11.19.2 Bio-Labs Business Overview
11.19.3 Bio-Labs Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.19.4 Bio-Labs Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Bio-Labs Recent Developments
11.20 Avimex Animal Health
11.20.1 Avimex Animal Health Corporation Information
11.20.2 Avimex Animal Health Business Overview
11.20.3 Avimex Animal Health Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.20.4 Avimex Animal Health Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Avimex Animal Health Recent Developments
11.21 MEVAC
11.21.1 MEVAC Corporation Information
11.21.2 MEVAC Business Overview
11.21.3 MEVAC Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.21.4 MEVAC Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 MEVAC Recent Developments
11.22 Biovac
11.22.1 Biovac Corporation Information
11.22.2 Biovac Business Overview
11.22.3 Biovac Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.22.4 Biovac Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Biovac Recent Developments
11.23 Atafen
11.23.1 Atafen Corporation Information
11.23.2 Atafen Business Overview
11.23.3 Atafen Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.23.4 Atafen Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Atafen Recent Developments
11.24 Dyntec
11.24.1 Dyntec Corporation Information
11.24.2 Dyntec Business Overview
11.24.3 Dyntec Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.24.4 Dyntec Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 Dyntec Recent Developments
11.25 RVSRI
11.25.1 RVSRI Corporation Information
11.25.2 RVSRI Business Overview
11.25.3 RVSRI Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.25.4 RVSRI Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 RVSRI Recent Developments
11.26 Medion
11.26.1 Medion Corporation Information
11.26.2 Medion Business Overview
11.26.3 Medion Inactivated Veterinary Vaccines Product Models, Descriptions and Specifications
11.26.4 Medion Inactivated Veterinary Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Medion Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Inactivated Veterinary Vaccines Industry Chain
12.2 Inactivated Veterinary Vaccines Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Inactivated Veterinary Vaccines Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Inactivated Veterinary Vaccines Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Inactivated Veterinary Vaccines Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Inactivated Veterinary Vaccines Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Adjuvanted, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Vaccine Combination, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Inactivated Veterinary Vaccines Revenue by Region (US$ Million), 2021-2026
Table 7. Global Inactivated Veterinary Vaccines Revenue by Region (US$ Million), 2027-2032
Table 8. Global Inactivated Veterinary Vaccines Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Table 9. Global Inactivated Veterinary Vaccines Sales by Region (K Dose), 2021-2026
Table 10. Global Inactivated Veterinary Vaccines Sales by Region (K Dose), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Inactivated Veterinary Vaccines Sales by Manufacturers (K Dose), 2021-2026
Table 13. Global Inactivated Veterinary Vaccines Sales Share by Manufacturers (2021-2026)
Table 14. Global Inactivated Veterinary Vaccines Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Inactivated Veterinary Vaccines Revenue, 2025
Table 18. Global Inactivated Veterinary Vaccines Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Inactivated Veterinary Vaccines Average Selling Price (ASP) by Manufacturers (US$/Dose), 2021-2026
Table 20. Key Manufacturers Inactivated Veterinary Vaccines Manufacturing Base and Headquarters
Table 21. Global Inactivated Veterinary Vaccines Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Inactivated Veterinary Vaccines Sales Volume by Type (K Dose), 2021-2026
Table 25. Global Inactivated Veterinary Vaccines Sales Volume by Type (K Dose), 2027-2032
Table 26. Global Inactivated Veterinary Vaccines Revenue by Type (US$ Million), 2021-2026
Table 27. Global Inactivated Veterinary Vaccines Revenue by Type (US$ Million), 2027-2032
Table 28. Global Inactivated Veterinary Vaccines Sales Volume by Adjuvanted (K Dose), 2021-2026
Table 29. Global Inactivated Veterinary Vaccines Sales Volume by Adjuvanted (K Dose), 2027-2032
Table 30. Global Inactivated Veterinary Vaccines Revenue by Adjuvanted (US$ Million), 2021-2026
Table 31. Global Inactivated Veterinary Vaccines Revenue by Adjuvanted (US$ Million), 2027-2032
Table 32. Global Inactivated Veterinary Vaccines Sales Volume by Vaccine Combination (K Dose), 2021-2026
Table 33. Global Inactivated Veterinary Vaccines Sales Volume by Vaccine Combination (K Dose), 2027-2032
Table 34. Global Inactivated Veterinary Vaccines Revenue by Vaccine Combination (US$ Million), 2021-2026
Table 35. Global Inactivated Veterinary Vaccines Revenue by Vaccine Combination (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Inactivated Veterinary Vaccines Sales by Application (K Dose), 2021-2026
Table 38. Global Inactivated Veterinary Vaccines Sales by Application (K Dose), 2027-2032
Table 39. Inactivated Veterinary Vaccines High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Inactivated Veterinary Vaccines Revenue by Application (US$ Million), 2021-2026
Table 41. Global Inactivated Veterinary Vaccines Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Inactivated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 45. North America Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Inactivated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Inactivated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 48. Europe Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Inactivated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Inactivated Veterinary Vaccines Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Inactivated Veterinary Vaccines Growth Accelerators and Market Barriers
Table 53. Southeast Asia Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Inactivated Veterinary Vaccines Investment Opportunities and Key Challenges
Table 55. Central and South America Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Inactivated Veterinary Vaccines Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Inactivated Veterinary Vaccines Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Merck Corporation Information
Table 59. Merck Description and Major Businesses
Table 60. Merck Product Models, Descriptions and Specifications
Table 61. Merck Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 62. Merck Sales Value Proportion by Product in 2025
Table 63. Merck Sales Value Proportion by Application in 2025
Table 64. Merck Sales Value Proportion by Geographic Area in 2025
Table 65. Merck Inactivated Veterinary Vaccines SWOT Analysis
Table 66. Merck Recent Developments
Table 67. Zoetis Corporation Information
Table 68. Zoetis Description and Major Businesses
Table 69. Zoetis Product Models, Descriptions and Specifications
Table 70. Zoetis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 71. Zoetis Sales Value Proportion by Product in 2025
Table 72. Zoetis Sales Value Proportion by Application in 2025
Table 73. Zoetis Sales Value Proportion by Geographic Area in 2025
Table 74. Zoetis Inactivated Veterinary Vaccines SWOT Analysis
Table 75. Zoetis Recent Developments
Table 76. Boehringer Ingelheim Corporation Information
Table 77. Boehringer Ingelheim Description and Major Businesses
Table 78. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 79. Boehringer Ingelheim Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 80. Boehringer Ingelheim Sales Value Proportion by Product in 2025
Table 81. Boehringer Ingelheim Sales Value Proportion by Application in 2025
Table 82. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2025
Table 83. Boehringer Ingelheim Inactivated Veterinary Vaccines SWOT Analysis
Table 84. Boehringer Ingelheim Recent Developments
Table 85. Ceva Corporation Information
Table 86. Ceva Description and Major Businesses
Table 87. Ceva Product Models, Descriptions and Specifications
Table 88. Ceva Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 89. Ceva Sales Value Proportion by Product in 2025
Table 90. Ceva Sales Value Proportion by Application in 2025
Table 91. Ceva Sales Value Proportion by Geographic Area in 2025
Table 92. Ceva Inactivated Veterinary Vaccines SWOT Analysis
Table 93. Ceva Recent Developments
Table 94. CAHIC Corporation Information
Table 95. CAHIC Description and Major Businesses
Table 96. CAHIC Product Models, Descriptions and Specifications
Table 97. CAHIC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. CAHIC Sales Value Proportion by Product in 2025
Table 99. CAHIC Sales Value Proportion by Application in 2025
Table 100. CAHIC Sales Value Proportion by Geographic Area in 2025
Table 101. CAHIC Inactivated Veterinary Vaccines SWOT Analysis
Table 102. CAHIC Recent Developments
Table 103. HVRI Corporation Information
Table 104. HVRI Description and Major Businesses
Table 105. HVRI Product Models, Descriptions and Specifications
Table 106. HVRI Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. HVRI Recent Developments
Table 108. Ringpu Biology Corporation Information
Table 109. Ringpu Biology Description and Major Businesses
Table 110. Ringpu Biology Product Models, Descriptions and Specifications
Table 111. Ringpu Biology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. Ringpu Biology Recent Developments
Table 113. Yebio Corporation Information
Table 114. Yebio Description and Major Businesses
Table 115. Yebio Product Models, Descriptions and Specifications
Table 116. Yebio Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Yebio Recent Developments
Table 118. DHN Corporation Information
Table 119. DHN Description and Major Businesses
Table 120. DHN Product Models, Descriptions and Specifications
Table 121. DHN Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. DHN Recent Developments
Table 123. WINSUN Corporation Information
Table 124. WINSUN Description and Major Businesses
Table 125. WINSUN Product Models, Descriptions and Specifications
Table 126. WINSUN Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. WINSUN Recent Developments
Table 128. Elanco Corporation Information
Table 129. Elanco Description and Major Businesses
Table 130. Elanco Product Models, Descriptions and Specifications
Table 131. Elanco Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Elanco Recent Developments
Table 133. Virbac Corporation Information
Table 134. Virbac Description and Major Businesses
Table 135. Virbac Product Models, Descriptions and Specifications
Table 136. Virbac Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Virbac Recent Developments
Table 138. Jinyu Bio-Technology Corporation Information
Table 139. Jinyu Bio-Technology Description and Major Businesses
Table 140. Jinyu Bio-Technology Product Models, Descriptions and Specifications
Table 141. Jinyu Bio-Technology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Jinyu Bio-Technology Recent Developments
Table 143. ChengDu Tecbond Corporation Information
Table 144. ChengDu Tecbond Description and Major Businesses
Table 145. ChengDu Tecbond Product Models, Descriptions and Specifications
Table 146. ChengDu Tecbond Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. ChengDu Tecbond Recent Developments
Table 148. CAVAC Corporation Information
Table 149. CAVAC Description and Major Businesses
Table 150. CAVAC Product Models, Descriptions and Specifications
Table 151. CAVAC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. CAVAC Recent Developments
Table 153. Kyoto Biken Laboratories Corporation Information
Table 154. Kyoto Biken Laboratories Description and Major Businesses
Table 155. Kyoto Biken Laboratories Product Models, Descriptions and Specifications
Table 156. Kyoto Biken Laboratories Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. Kyoto Biken Laboratories Recent Developments
Table 158. FATRO Corporation Information
Table 159. FATRO Description and Major Businesses
Table 160. FATRO Product Models, Descriptions and Specifications
Table 161. FATRO Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. FATRO Recent Developments
Table 163. Vaksindo Corporation Information
Table 164. Vaksindo Description and Major Businesses
Table 165. Vaksindo Product Models, Descriptions and Specifications
Table 166. Vaksindo Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Vaksindo Recent Developments
Table 168. Bio-Labs Corporation Information
Table 169. Bio-Labs Description and Major Businesses
Table 170. Bio-Labs Product Models, Descriptions and Specifications
Table 171. Bio-Labs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Bio-Labs Recent Developments
Table 173. Avimex Animal Health Corporation Information
Table 174. Avimex Animal Health Description and Major Businesses
Table 175. Avimex Animal Health Product Models, Descriptions and Specifications
Table 176. Avimex Animal Health Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Avimex Animal Health Recent Developments
Table 178. MEVAC Corporation Information
Table 179. MEVAC Description and Major Businesses
Table 180. MEVAC Product Models, Descriptions and Specifications
Table 181. MEVAC Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 182. MEVAC Recent Developments
Table 183. Biovac Corporation Information
Table 184. Biovac Description and Major Businesses
Table 185. Biovac Product Models, Descriptions and Specifications
Table 186. Biovac Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 187. Biovac Recent Developments
Table 188. Atafen Corporation Information
Table 189. Atafen Description and Major Businesses
Table 190. Atafen Product Models, Descriptions and Specifications
Table 191. Atafen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 192. Atafen Recent Developments
Table 193. Dyntec Corporation Information
Table 194. Dyntec Description and Major Businesses
Table 195. Dyntec Product Models, Descriptions and Specifications
Table 196. Dyntec Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 197. Dyntec Recent Developments
Table 198. RVSRI Corporation Information
Table 199. RVSRI Description and Major Businesses
Table 200. RVSRI Product Models, Descriptions and Specifications
Table 201. RVSRI Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 202. RVSRI Recent Developments
Table 203. Medion Corporation Information
Table 204. Medion Description and Major Businesses
Table 205. Medion Product Models, Descriptions and Specifications
Table 206. Medion Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 207. Medion Recent Developments
Table 208. Key Raw Materials Distribution
Table 209. Raw Materials Key Suppliers
Table 210. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 211. Milestones in Production Technology Evolution
Table 212. Distributors List
Table 213. Market Trends and Market Evolution
Table 214. Market Drivers and Opportunities
Table 215. Market Challenges, Risks, and Restraints
Table 216. Research Programs/Design for This Report
Table 217. Key Data Information from Secondary Sources
Table 218. Key Data Information from Primary Sources

List of Figures
Figure 1. Inactivated Veterinary Vaccines Product Picture
Figure 2. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Inactivated Viral Vaccines Product Picture
Figure 4. Inactivated Bacterial Vaccines Product Picture
Figure 5. Other Product Picture
Figure 6. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Adjuvanted, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Oil-Adjuvanted Inactivated Vaccines Product Picture
Figure 8. Aluminum-Adjuvanted Inactivated Vaccines Product Picture
Figure 9. Other Product Picture
Figure 10. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Vaccine Combination, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Vaccines Product Picture
Figure 12. Multivalent Vaccines Product Picture
Figure 13. Combination Vaccines Product Picture
Figure 14. Global Inactivated Veterinary Vaccines Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Farm Animal
Figure 16. Companion Animal
Figure 17. Inactivated Veterinary Vaccines Report Years Considered
Figure 18. Global Inactivated Veterinary Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 19. Global Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 20. Global Inactivated Veterinary Vaccines Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 21. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Region (2021-2032)
Figure 22. Global Inactivated Veterinary Vaccines Sales (K Dose), 2021-2032
Figure 23. Global Inactivated Veterinary Vaccines Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Figure 24. Global Inactivated Veterinary Vaccines Sales Market Share by Region (2021-2032)
Figure 25. Top 5 and Top 10 Manufacturers Inactivated Veterinary Vaccines Sales Volume Market Share in 2025
Figure 26. Global Inactivated Veterinary Vaccines Revenue-Based Market Share Ranking (2025)
Figure 27. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 28. Inactivated Viral Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 29. Inactivated Bacterial Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 30. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 31. Global Inactivated Veterinary Vaccines Sales Volume-Based Market Share by Type (2021-2032)
Figure 32. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Inactivated Veterinary Vaccines ASP by Type (US$/Dose), 2021-2032
Figure 34. Global Inactivated Veterinary Vaccines Sales Volume-Based Market Share by Adjuvanted (2021-2032)
Figure 35. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Adjuvanted (2021-2032)
Figure 36. Global Inactivated Veterinary Vaccines ASP by Adjuvanted (US$/Dose), 2021-2032
Figure 37. Global Inactivated Veterinary Vaccines Sales Volume-Based Market Share by Vaccine Combination (2021-2032)
Figure 38. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Vaccine Combination (2021-2032)
Figure 39. Global Inactivated Veterinary Vaccines ASP by Vaccine Combination (US$/Dose), 2021-2032
Figure 40. Global Inactivated Veterinary Vaccines Sales Market Share by Application (2021-2032)
Figure 41. Global Inactivated Veterinary Vaccines Revenue-Based Market Share by Application (2021-2032)
Figure 42. Global Inactivated Veterinary Vaccines ASP by Application (US$/Dose), 2021-2032
Figure 43. North America Inactivated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 44. North America Inactivated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 45. North America Top 5 Manufacturers Inactivated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 46. North America Inactivated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 47. North America Inactivated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 48. US Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 49. Canada Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 50. Mexico Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 51. Europe Inactivated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 52. Europe Inactivated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 53. Europe Top 5 Manufacturers Inactivated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 54. Europe Inactivated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 55. Europe Inactivated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 56. Germany Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 57. France Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 58. U.K. Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 59. Italy Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 60. Russia Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 61. Asia-Pacific Inactivated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 62. Asia-Pacific Inactivated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 63. Asia-Pacific Top 8 Manufacturers Inactivated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 64. Asia-Pacific Inactivated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 65. Asia-Pacific Inactivated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 66. Indonesia Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 67. Japan Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 68. South Korea Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 69. China Taiwan Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 70. India Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 71. Central and South America Inactivated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 72. Central and South America Inactivated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 73. Central and South America Top 5 Manufacturers Inactivated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 74. Central and South America Inactivated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 75. Central and South America Inactivated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 76. Brazil Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 77. Argentina Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 78. Middle East, and Africa Inactivated Veterinary Vaccines Sales YoY (K Dose), 2021-2032
Figure 79. Middle East and Africa Inactivated Veterinary Vaccines Revenue YoY (US$ Million), 2021-2032
Figure 80. Middle East and Africa Top 5 Manufacturers Inactivated Veterinary Vaccines Sales Revenue (US$ Million) in 2025
Figure 81. Middle East and Africa Inactivated Veterinary Vaccines Sales Volume (K Dose) by Application (2021-2032)
Figure 82. Middle East and Africa Inactivated Veterinary Vaccines Sales Revenue (US$ Million) by Application (2021-2032)
Figure 83. GCC Countries Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 84. Turkey Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 85. Egypt Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 86. South Africa Inactivated Veterinary Vaccines Revenue (US$ Million), 2021-2032
Figure 87. Inactivated Veterinary Vaccines Industry Chain Mapping
Figure 88. Regional Inactivated Veterinary Vaccines Manufacturing Base Distribution (%)
Figure 89. Global Inactivated Veterinary Vaccines Production Market Share by Region (2021-2032)
Figure 90. Inactivated Veterinary Vaccines Production Process
Figure 91. Regional Inactivated Veterinary Vaccines Production Cost Structure
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed